These pharma stocks have gone in different directions in the last year, but both hold promise for forward-thinking investors.
These healthcare stocks offer high risk and high reward, but they aren't nearly as risky as penny stocks.
The small-cap biopharmaceutical company announced a public stock offering.
The company announced a public stock offering as it prepares for a potential regulatory approval in 2020.
The biggest source of uncertainty has been removed, allowing Wall Street to focus on the company's growth and financials. But investors should be careful what they wish for.
These two stocks are supported by solid long-term opportunities, but they couldn't be more different.
The world's leading lithium producer and one of America's greenest electric utilities are great investments for investors with a long-term mindset.
Interim results from an early-stage study of its wet age-related macular degeneration treatment look promising.
These three stocks have major events coming up this month -- and it's not just the release of earnings that investors will be watching.
Recession or not, these two utilities will keep delivering the electricity, natural gas, and water that make modern life possible.
The pharmaceutical stock soared after being approached for an acquisition, but has tanked in the weeks since management announced it has declined the offer.
Investors initially were displeased with full-year 2019 operating results, but shares have bounced back in February.
A failed study disappointed investors, but the company's pipeline should withstand the blow.
Investors continue to gobble up shares of the fast-growing company.
The speciality pharmaceutical company purchased the full rights to an important drug product.
Despite reports of positive late-stage results for an important drug candidate, Wall Street was hoping for more.
Investors began to question the excessive market valuation for the early-stage biopharma, but the company still has plenty of potential.
GasLog offered mixed comments on the state of the market, announced major impairment charges, and slashed its distribution.
The healthcare company reported solid quarterly earnings and raised its fiscal full-year 2020 guidance.
The drug manufacturer is doubling down on biologic drugs to grow profits, but not all of the additional earnings will trickle down the income statement for individual investors.